EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Completed · Phase 4 · NCT04998604
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Asthma
At a glance
- Research payments reported, 2025
- $219,506
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 360
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab (drug), Omalizumab (drug), Placebo (drug)
- Dates
- Started 2021-09-27; completion 2024-12-27
- Results posted
- Yes
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives * To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab * To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab * To evaluate the effect of dupilumab on CRSw…
From ClinicalTrials.gov, last updated 2025-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $219,506 in research payments for this study in 2025 (31 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Arthur W. Wu, M.D. ENT (Otolaryngology) · Los Angeles, CA
- Seong H. Cho, M.D. Allergy & Immunology · Tampa, FL
- Anju Peters, M.D. Allergy & Immunology · Chicago, IL
- Keith D. Forwith, MD ENT (Otolaryngology) · Louisville, KY
- Christine B. Franzese, M.D. ENT (Otolaryngology) · Columbia, MO
- Blanka Kaplan, MD Pediatrics · Great Neck, NY
- Martha M. Tarpay, MD Allergy & Immunology · Oklahoma City, OK
- Shyam R. Joshi, M.D. Allergy & Immunology · Portland, OR
- Amber Luong, M.D., PH.D ENT (Otolaryngology) · Houston, TX
- Joseph K. Han, MD ENT (Otolaryngology) · Norfolk, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of South Florida $46,105
- Martha Tarpay MD Allergy Asthma and Clinical Researc Center $43,340
- Northwestern University $32,316
- The Feinstein Institute for Medical Research $27,516
- Cedars-Sinai Medical Center, CA $22,591
- University of Missouri Health Care, MO $19,961
- Ohsu Hospital and Clinics, OR $13,610
- Eastern Virginia Medical School Department of Internal Medicine $6,030
- Advanced Ent and Allergy $3,774
- The University of Texas Health Scie Center at Houston $2,764
- $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.